A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer

Abstract

Background: S-1, a novel oral fluoropyrimidine, is active in the treatment of non-small cell lung cancer (NSCLC). However, data on S-1 for elderly patients with NSCLC are insufficient. Methods: Eligibility criteria were no prior chemotherapy, stage IIIB or IV NSCLC, performance status 0-1, age >70 years, and adequate hematological, hepatic, and renal functions. Patients received S-1 (40 mg/m² twice a day) for 28 consecutive days. This schedule was repeated every 6 weeks. The primary end point was the tumor response rate. Results: Thirty-two patients were enrolled and 31 patients were evaluable for response. The patients' median age was 80 years (range: 71-88). The response rate was 22.6% (95% CI: 11-38). Neutropenia, anemia, thrombocytopenia, febrile neutropenia, and diarrhea of grade ≥3 occurred in 6, 6, 10, 3, and 3%, respectively. Conclusions: In elderly patients with previously untreated advanced NSCLC, S-1 appears to be well tolerated and demonstrates encouraging activity.

Efficacy of S-1 after Pemetrexed in Patients with Non-small Cell Carcinoma: A Retrospective Multi-institutional Analysis

“…It was presumed that one of the mechanisms of crossresistance between PEM and S-1 was reduction of TS expression due to prior PEM treatment. To compare this study, previous reports about S-1 monotherapy were checked up (Table 3) (7,(9)(10)(11)(12)(13)(14). Interestingly, in two studies about e cacy of S-1 whose registration period was prior to 2009, S-1 showed higher ORR in adenocarcinoma or non-SQ than in squamous cell carcinoma (11,12).…”

A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non–small cell lung cancer (JCOG 0707)

“…S-1 is a newer drug in the same class, combining fluoropyrimidines and DPD inhibition. Its single-agent response rate against advanced NSCLC exceeds 20% [13][14][15] versus less than 10% in UFT. 8,9 In fact, postoperative adjuvant therapy with S-1 was reported to be superior to UFT with respect to RFS in rectal cancer.…”

Ginsenoside Rg3 Serves as an Adjuvant Chemotherapeutic Agent and VEGF Inhibitor in the Treatment of Non‐Small Cell Lung Cancer: A Meta‐Analysis and Systematic Review

“…These regimens combine cisplatin or carboplatin with cytotoxic drugs such as paclitaxel, docetaxel, gemcitabine, vinorelbine, and pemetrexed [ 37 ]. Cyclophosphamide [ 38 ], S-1 [ 39 ], and etoposide [ 40 ] are also treatment approaches for advanced NSCLC. However, many factors affect the curative potential of chemotherapy.…”